|
|
The 1st World Congress on
Controversies in Hematology (COHEM)
Rome, Italy, 2-5 September, 2010 |
|
| |
| Scientific Program |
 |
|
|
|
Thursday, September 2, 2010 |
|
18:00-19:30 |
WELCOME RECEPTION |
|
Friday, September 3, 2010 |
|
Session 1 |
08:30-10:00 |
PLENARY SESSION 1 |
|
|
08:30-08:40 |
Opening Remarks
E. Rachmilewitz, Israel & G. Saglio, Italy |
|
08:40-09:20 |
Did we substantially improve MDS therapy in the last decade? |
|
08:40-08:45 |
Moderator: E. Rachmilewitz, Israel |
|
08:45-08:55 |
Yes: H. Kantarjian, USA |
|
08:55-09:05 |
No: C. Schiffer, USA |
|
09:05-09:20 |
Discussion |
|
09:20-10:00 |
Is there a role for SCT in Multiple Myeloma? |
|
09:20-09:25 |
Moderator: J.F. San-Miguel, Spain |
|
09:25-09:35 |
Yes: B. Barlogie, USA |
|
09:35-09:45 |
No: M. Boccadoro, Italy |
|
09:45-10:00 |
Discussion |
| Session 2 |
10:30-12:30 |
ACUTE MYELOID LEUKEMIA (AML) I
|
|
10:30-11:30 |
About targeted therapies in AML: Have standard treatments reached their limits? |
|
10:30-10:35 |
Moderator: S. Amadori, Italy |
|
10:35-10:50 |
Yes: A. Burnett, UK |
|
10:50-11:05 |
No: B. Löwenberg, The Netherlands |
|
11:05-11:30 |
Discussion |
|
11:30-12:30 |
Should the therapy of AML be driven by MRD quantification? |
|
11:30-11:35 |
Moderator: B. Löwenberg, The Netherlands |
|
11:35-11:50 |
Yes: S. Amadori, Italy |
|
11:50-12:05 |
No: C. Schiffer, USA |
|
12:05-12:30 |
Discussion |
CURRENT PROGRESS IN CML THERAPY
|
|
13:15 - 14:30 |
Satellite Symposium by Novartis |
|
|
Chairpersons: |
M. Baccarani, Italy
R. Hehlmann, Germany |
| 13:15-13:20 |
Welcome |
|
13:20-13:35 |
Molecular Monitoring of CML: Progress in standardization
F. Pane, Italy |
| 13:35-13:45 |
Discussion |
|
|
Second generation TKIs as first-line therapy: ENESTnd
A. Hochhaus, Germany |
| 14:00-14:10 |
Discussion |
|
|
Nilotinib: A selective choice for resistant and Intolerant patients to Imatinib
M. Breccia, Italy |
| 14:25-14:30 |
Closing | |
|
Session 3 |
14:30-16:00 |
ACUTE MYELOID LEUKEMIA (AML) II and
ACUTE PROMYELOCYTIC LEUKEMIA (APL)
|
|
14:30-15:15 |
Do we require chemotherapy to cure APL? |
|
14:30-14:35 |
Moderator: A. Burnett, UK |
|
14:35-14:45 |
Yes: M.A. Sanz, Spain |
|
14:45-14:55 |
No: F. Lo-Coco, Italy |
|
14:55-15:15 |
Discussion |
|
15:15-16:00 |
Can novel prognostic markers predict for success and guide therapy in AML? |
|
15:15-15:20 |
Moderator: C. Schiffer, USA |
|
15:20-15:30 |
Yes: D. Grimwade, UK |
|
15:30-15:40 |
No: A. Burnett, UK |
|
15:40-16:00 |
Discussion |
|
16:00-16:10 Best Abstract Awards Ceremony |
|
Session 4 |
16:30-18:00 |
ACUTE LYMPHATIC LEUKEMIA (ALL) |
|
16:30-17:15 |
Is the efficacy of the pediatric-like protocols for ALL superior to the protocols for adult ALL? |
|
16:30-16:35 |
Moderator: R. Foà, Italy |
|
16:35-16:45 |
Yes: J.P. Marie, France |
|
16:45-16:55 |
No: J. Ribera, Spain |
|
16:55-17:15 |
Discussion |
|
17:15-18:00 |
Should the induction for Ph+ ALL be based on TKI alone or TKI plus chemotherapy? |
|
17:15-17:20 |
Moderator: J.P. Marie, France |
|
17:20-17:30 |
TKI alone: R. Foà, Italy |
|
17:30-17:40 |
TKI plus chemotherapy: O. Ottmann, Germany |
|
17:40-18:00 |
Discussion |
|
Session 5 |
10:30-12:30 |
CHRONIC LYMPHATIC LEUKEMIA (CLL) |
|
10:30-11:30 |
Is eradication of MRD feasible and worthwhile in CLL? |
|
10:30-10:35 |
Moderator: K. Rai, USA |
|
10:35-10:50 |
Yes: G. Marti, USA |
|
10:50-11:05 |
No: G. Gaidano, Italy |
|
11:05-11:30 |
Discussion |
|
11:30-12:30 |
Is the “wait and watch” philosophy still practical in the treatment of CLL even in younger patients? |
|
11:30-11:35 |
Moderator: A. Polliack, Israel |
|
11:35-11:50 |
Yes: K. Rai, USA |
|
11:50-12:05 |
No: F. Caligaris-Cappio, Italy |
|
12:05-12:30 |
Discussion |
|
Session 6 |
14:30-16:00 |
INDOLENT NON-HODGKIN LYMPHOMA (NHL) |
|
14:30-15:15 |
Is there a role for Rituximab in maintenance treatment in non-follicular indolent lymphomas? |
|
14:30-14:35 |
Moderator: C. Portlock, USA |
|
14:35-14:45 |
Yes: A. Hagenbeek, The Netherlands |
|
14:45-14:55 |
No: C. Buske, Germany |
|
14:55-15:15 |
Discussion |
|
15:15-16:00 |
Is molecular remission the goal in first line therapy of all patients with indolent non-Hodgkin lymphoma? |
|
15:15-15:20 |
Moderator: A. Hagenbeek, The Netherlands |
|
15:20-15:30 |
Yes: P. Corradini, Italy |
|
15:30-15:40 |
No: C. Tarella, Italy |
|
15:40-16:00 |
Discussion |
|
Session 7 |
16:30-18:00 |
MULTIPLE MYELOMA (MM) |
|
16:30-17:15 |
Multiple Myeloma in patients < 70 years: Cure vs. disease control |
|
16:30-16:35 |
Moderator: N. Kröger, Germany |
|
16:35-16:45 |
Cure: J.F. San-Miguel, Spain |
|
16:45-16:55 |
Control: M. Boccadoro, Italy |
|
16:55-17:15 |
Discussion |
|
17:15-18:00 |
Should therapy for newly diagnosed MM be risk adapted? |
|
17:15-17:20 |
Moderator: M. Boccadoro, Italy |
|
17:20-17:30 |
Yes: B. Barlogie, USA |
|
17:30-17:40 |
No: E. Terpos, Greece |
|
17:40-18:00 |
Discussion |
|
Saturday, September 4, 2010 |
|
Session 8 |
08:30-10:00 |
STEM CELL TRANSPLANTATION (SCT) I
The role of Allogeneic SCT (AlloSCT) in Hematological Malignancies |
|
08:30-09:15 |
How should we treat a 60 year old patient with Myelodysplastic syndrome? |
|
08:30-08:35 |
Moderator: M. Martelli, Italy |
|
08:35-08:45 |
AlloSCT: N. Kröger, Germany |
|
08:45-08:55 |
Conventional Therapy: U. Platzbecker, Germany |
|
08:55-09:15 |
Discussion |
|
09:15-10:00 |
Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients? |
|
09:15-09:20 |
Moderator: W. Arcese, Italy |
|
09:20-09:30 |
All: A. Goldstone, UK |
|
09:30-09:40 |
Only high risk: D. Hoelzer, Germany |
|
09:40-10:00 |
Discussion |
|
Session 9 |
10:30-12:30 |
STEM CELL TRANSPLANTATION (SCT) II
Alternative Donor and Reduced Intensity Conditioning (RIC) AlloSCT |
|
10:30-11:40 |
Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available? |
|
10:30-10:35 |
Moderator: A. Rambaldi, Italy |
|
10:35-10:50 |
CBT: W. Arcese, Italy |
|
10:50-11:05 |
Haplo: M. Martelli, Italy |
|
11:05-11:20 |
MUD: A. Bacigalupo, Italy |
|
11:20-11:40 |
Discussion |
|
11:40-12:30 |
Should we use AlloSCT in Acute Myeloid Leukemia RIC or Myeloablative preparative protocols? |
|
11:40-11:45 |
Moderator: A. Bacigalupo, Italy |
|
11:45-12:00 |
RIC: A. Nagler, Israel |
|
12:00-12:15 |
Myeloablative: A. Rambaldi, Italy |
|
12:15-12:30 |
Discussion |
POTENTIAL NEW STRATEGIES FOR FIRST-LINE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
|
13:15 - 14:30 |
Satellite Symposium by Bristol-Myers Squibb / Otsuka |
|
| 13:15-13:20 |
Welcome And Outline Of Program
M. Baccarani, Italy |
| 13:20-13:40 |
Why Is There A Need To Optimize first-Line Treatment Of CML-CP?
A. Hochhaus, Germany |
| 13:40-14:00 |
Can New Investigational Strategies Help Optimize Treatment For Newly Diagnosed CML-CP Patients?
M. Baccarani, Italy |
|
14:00-14:20 |
Perspectives On Strategies For First-Line Treatment Of CML-CP
G. Saglio, Italy |
| 14:20-14:30 |
Panel Discussion And Audience Questions
Moderator: M. Baccarani, Italy | |
|
Session 10 |
14:30-16:00 |
MDS |
|
14:30-15:15 |
Do hypomethylating agents improve survival in patients with high risk myelodysplastic syndromes? |
|
14:30-14:35 |
Moderator: G. Leone, Italy |
|
14:35-14:45 |
Yes: V. Santini, Italy |
|
14:45-14:55 |
No: M. Cazzola, Italy |
|
14:55-15:15 |
Discussion |
|
15:15-16:00 |
Is there a rationale for iron chelation therapy in MDS? |
|
15:15-15:20 |
Moderator: E. Rachmilewitz, Israel |
|
15:20-15:30 |
Yes: N. Gattermann, Germany |
|
15:30-15:40 |
No: A. Tefferi, USA |
|
15:40-16:00 |
Discussion |
|
Session 11 |
16:30-18:00 |
HODGKIN AND NON-HODGKIN LYMPHOMA |
|
16:30-17:15 |
Has PET/CT an established role in the management of HD and NHLs? |
|
16:30-16:35 |
Moderator: M. Björkholm, Sweden |
|
16:35-16:45 |
Yes: M. Hutchings, Denmark |
|
16:45-16:55 |
No: U. Vitolo, Italy |
|
16:55-17:15 |
Discussion |
|
17:15-18:00 |
Does molecular outcome prediction in DLBCL add clinical value? |
|
17:15-17:20 |
Moderator: M. Björkholm, Sweden |
|
17:20-17:30 |
Yes: C. Gisselbrecht, France |
|
17:30-17:40 |
No: M. Pfreundschuh, Germany |
|
17:40-18:00 |
Discussion |
|
Session 12 |
08:30-10:00 |
COAGULATION |
|
08:30-09:15 |
Are there indications for thrombophylaxis in cancer patients during and after chemotherapy? |
|
08:30-08:35 |
Moderator: M.M. Samama, France |
|
08:35-08:45 |
Yes: A. Falanga, Italy |
|
08:45-08:55 |
No: A. Kakkar, UK |
|
08:55-09:15 |
Discussion |
|
09:15-10:00 |
Is there still a role for splenectomy in ITP? |
|
09:15-09:20 |
Moderator: A. Falanga, Italy |
|
09:20-09:30 |
Yes: B. Godeau, France |
|
09:30-09:40 |
No: J. Bussel, USA |
|
09:40-10:00 |
Discussion |
|
Session 13 |
10:30-12:30 |
CHRONIC MYELOID LEUKEMIA (CML) I |
|
10:30-11:10 |
Is mutation analysis of BCR ABL of any value in clinical management of CML patients? |
|
10:30-10:35 |
Moderator: J. Goldman, UK |
|
10:35-10:45 |
Yes: A. Hochhaus, Germany |
|
10:45-10:55 |
No: D. Marin, UK |
|
10:55-11:10 |
Discussion |
|
11:10-11:50 |
Should first line imatinib treatment be optimized by combination with IFN or by higher imatinib dose? |
|
11:10-11:15 |
Moderator: A. Hochhaus, Germany |
|
11:15-11:25 |
Combination with IFN: F. Guilhot, France |
|
11:25-11:35 |
Higher initial imatinib dose: R. Hehlmann, Germany |
|
11:35-11:50 |
Discussion |
|
11:50-12:30 |
On the road to cure CML, does it matter to hit different pathways? |
|
11:50-11:55 |
Moderator: R. Hehlmann, Germany |
|
11:55-12:05 |
Yes: N. Shah, USA |
|
12:05-12:15 |
No: G. Saglio, Italy |
|
12:15-12:30 |
Discussion |
|
Session 14 |
14:30-16:00 |
CHRONIC MYELOID LEUKEMIA (CML) II |
|
14:30-15:15 |
Will second generation TKIs substitute imatinib as first line treatment of CML? |
|
14:30-14:35 |
Moderator: R. Hehlmann, Germany |
|
14:35-14:45 |
Yes: M. Baccarani, Italy |
|
14:45-14:55 |
No: H. Kantarjian, USA |
|
14:55-15:15 |
Discussion |
|
15:15-16:00 |
Can we eventually stop TKI in all CML patients? |
|
15:15-15:20 |
Moderator: M. Baccarani, Italy |
|
15:20-15:30 |
Yes: F. Mahon, France |
|
15:30-15:40 |
No: J. Goldman, UK |
|
15:40-16:00 |
Discussion |
|
Session 15 |
16:30-18:30 |
HEMOGLOBINOPATHIES & PNH |
|
16:30-16:50 |
Pros and cons of gene therapy in beta-thalassemia |
|
16:30-16:35 |
Moderator: L. Luzzatto, Italy |
|
16:35-16:50 |
Lecture: S. Rivella, USA |
|
16:50-17:10 |
The controversies in the use of chelating drugs for the treatment of iron overload affect the morbidity and mortality of thalassaemia and other transfused patients worldwide |
|
16:50-16:55 |
Moderator: E. Rachmilewitz, Israel |
|
16:55-17:10 |
Lecture: G. Kontoghiorghes, Cyprus |
|
17:10-17:50 |
How far one should go with iron chelation in thalassemia? Is iron deficiency indicated? |
|
17:10-17:15 |
Moderator: E. Rachmilewitz, Israel |
|
17:15-17:25 |
Yes: V. Berdoukas, Greece |
|
17:25-17:35 |
No: M.D. Cappellini, Italy |
|
17:35-17:50 |
Discussion |
|
17:50-18:30 |
Do the benefits of complement blockade extend to all patients with PNH clone? |
|
17:50-17:55 |
Moderator: M.D. Cappellini, Italy |
|
17:55-18:05 |
Yes: A.M. Risitano, Italy |
|
18:05-18:15 |
No: L. Luzzatto, Italy |
|
18:15-18:30 |
Discussion |
|
Sunday, September 5, 2010 |
|
Session 16 |
08:30-10:00 |
MYELO PROLIFERATIVE NEOPLAMS (MPNs) |
|
08:30-09:15 |
Are JAK2 positive PV, ET and IM different diseases? |
|
08:30-08:35 |
Moderator: A. Tefferi, USA |
|
08:35-08:45 |
Yes: W. Vainchenker, France |
|
08:45-08:55 |
No: A.M. Vannucchi, Italy |
|
08:55-09:15 |
Discussion |
|
09:15-10:00 |
Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferative neoplasms? |
|
09:15-09:20 |
Moderator: W. Vainchenker, France |
|
09:20-09:30 |
Yes: A. Tefferi, USA |
|
09:30-09:40 |
No: T. Barbui, Italy |
|
09:40-10:00 |
Discussion |
|
Session 17 |
08:30-10:00 |
INFECTIONS |
|
08:30-09:15 |
Is there a role for empirical or pre-emptive antifungal treatment in patients with hematological malignancies? |
|
08:30-08:35 |
Moderator: F. Menichetti, Italy |
|
08:35-08:45 |
Yes: B. de Pauw, The Netherlands |
|
08:45-08:55 |
No: A. Prentice, UK |
|
08:55-09:15 |
Discussion |
|
09:15-10:00 |
Is monitoring of azole concentrations of clinical value in pts with hematological malignancies? |
|
09:15-09:20 |
Moderator: B. de Pauw, The Netherlands |
|
09:20-09:30 |
Yes: F. Menichetti, Italy |
|
09:30-09:40 |
No: P. Donnelly, The Netherlands |
|
09:40-10:00 |
Discussion |
|
Session 18 |
10:30-12:30 |
PLENARY SESSION 18 |
|
10:30-11:05 |
Is there a role of biologic prognostic markers in the treatment of CLL? |
|
10:30-10:35 |
Moderator: E. Rachmilewitz, Israel |
|
10:35-10:45 |
For: R. Foà, Italy |
|
10:45-11:55 |
Against: K. Rai, USA |
|
11:55-11:05 |
Discussion |
|
11:05-11:40 |
Are there sufficient indications for switching to new anticoagulant agents? |
|
11:05-11:10 |
Moderator: G. Saglio, Italy |
|
11:10-11:20 |
For: M.M. Samama, France |
|
11:20-11:30 |
Against: A. Falanga, Italy |
|
11:30-11:40 |
Discussion |
|
11:40-12:15 |
Which is the best chemotherapy regimen in Hodgkin Lymphoma? |
|
11:40-11:45 |
Moderator: D. Straus, USA |
|
11:45-11:55 |
ABVD: A. Levis, Italy |
|
11:55-12:05 |
BEACOPP: V. Diehl, Germany |
|
12:05-12:15 |
Discussion |
|
12:15-12:30 |
Is chemotherapy alone sufficient for the treatment of Hodgkin Lymphoma? |
|
12:15-12:30 |
Lecture: D. Straus, USA |
|
|
|
|
WebStudio.co.il